Literature DB >> 11517416

The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS.

M D Geschwind1, R I Skolasky, W S Royal, J C McArthur.   

Abstract

To explore the respective roles of highly active antiretroviral therapy (HAART) and alpha-interferon in improving survival of patients with AIDS-related PML, we retrospectively analyzed all patients with AIDS and PML who were referred to Johns Hopkins University HIV Neurology Program from 1985 to 2000. For 97 evaluable patients, we compared survival of those who were on HAART (three or more antiretroviral drugs) to those who were not on HAART. The effect of alpha-interferon was also studied. Multivariate analysis showed no difference in survival among patients on none, one, or two forms of antiretrovirals; however, survival was significantly greater for those on HAART. Whereas alpha-interferon use was shown to be associated with longer survival (P < 0.057), this effect was not independent of the effects of HAART. HAART significantly increases survival for patients with PML and AIDS; however, alpha-interferon does not appear to provide additional benefit.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11517416     DOI： 10.1080/13550280152537238

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   2.643


  16 in total

1.  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.

Authors:  J M Tassie; J Gasnault; M Bentata; J Deloumeaux; F Boué; E Billaud; D Costagliola
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.

Authors:  D B Clifford; C Yiannoutsos; M Glicksman; D M Simpson; E J Singer; P J Piliero; C M Marra; G S Francis; J C McArthur; K L Tyler; A C Tselis; N E Hyslop
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

Review 3.  Progressive multifocal leukoencephalopathy.

Authors:  J R Berger; E O Major
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

Review 4.  [Progressive multifocal leukoencephalopathy in AIDS. Overview and retrospective analysis of 17 patients].

Authors:  S Happe; N Lünenborg; C H Rickert; C Heese; D Reichelt; G Schuierer; C Schul; I W Husstedt
Journal:  Nervenarzt       Date:  2000-02       Impact factor: 1.214

5.  Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.

Authors:  W Tantisiriwat; P Tebas; D B Clifford; W G Powderly; C J Fichtenbaum
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

6.  Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy.

Authors:  A De Luca; A Ammassari; A Cingolani; M L Giancola; A Antinori
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

7.  Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy.

Authors:  P Cinque; S Casari; D Bertelli
Journal:  N Engl J Med       Date:  1998-09-17       Impact factor: 91.245

8.  Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response.

Authors:  B Giudici; B Vaz; S Bossolasco; S Casari; A M Brambilla; W Lüke; A Lazzarin; T Weber; P Cinque
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

9.  Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

Authors:  C D Hall; U Dafni; D Simpson; D Clifford; P E Wetherill; B Cohen; J McArthur; H Hollander; C Yainnoutsos; E Major; L Millar; J Timpone
Journal:  N Engl J Med       Date:  1998-05-07       Impact factor: 91.245

Review 10.  [Cidofovir (vistide) in therapy of progressive multifocal leukoencephalopathy in AIDS. Review of the literature and report of 2 cases].

Authors:  S Happe; M Besselmann; P Matheja; C H Rickert; G Schuierer; D Reichelt; I W Husstedt
Journal:  Nervenarzt       Date:  1999-10       Impact factor: 1.214
View more
  26 in total

Review 1.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 2.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

3.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

4.  Case 15: when a stroke is not a stroke.

Authors:  W Bryan Burnette
Journal:  MedGenMed       Date:  2007-01-30

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 6.  AIDS-associated progressive multifocal leukoencephalopathy : current management strategies.

Authors:  Mark T M Roberts
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

8.  Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells.

Authors:  Moti L Chapagain; Laarni Sumibcay; Ulziijargal Gurjav; Pakieli H Kaufusi; Richard E Kast; Vivek R Nerurkar
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

Review 9.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

10.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

Authors:  W Royal; B Dupont; D McGuire; L Chang; K Goodkin; T Ernst; M J Post; D Fish; G Pailloux; H Poncelet; M Concha; L Apuzzo; E Singer
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.